Home » News » Drug Sponsors » Taro rejects Sun Pharma offer

Taro rejects Sun Pharma offer

Thursday, July 19, 2012

The special committee of the board of directors of Taro Pharmaceutical Industries unanimously rejected the Oct. 18, 2011, unsolicited, non-binding offer from Sun Pharmaceutical Industries—to purchase all of the issued and outstanding shares of Taro not currently held by Sun Pharma for $24.50 per share—as inadequate and not in the best interests of Taro’s minority shareholders.

The special committee reached its conclusion after careful consideration, including a thorough review of Taro’s business and prospects with its independent financial advisor legal counsel.

 

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!